Transforming Inflammatory Bowel Disease Care: A Bispecific Nanobody Targeting Both IL-23 and TNF

VHH-P525 is a next-generation, humanized nanobody designed to target both the Interleukin 23 complex (IL-23) and tumor necrosis factor (TNF), offering a novel therapeutic solution for inflammatory bowel disease. Currently in the Biological Testing development stage, this bispecific construct combines two affinity-matured single-domain antibodies with specificity for human IL-23 (p19 subunit) and TNF. By addressing key inflammatory pathways, VHH-P525 demonstrates significant promise in modulating immune responses driving inflammatory bowel disease pathology.

Licensing Opportunity

VHH-P525 is available for out-licensing and collaborative partnerships. We welcome discussions with organizations interested in advancing innovative therapeutics for inflammatory bowel disease through strategic collaborations.

Development Phase

Modality

VHH-P525 represents a bispecific nanobody modality, built from two single-domain antibodies with high affinity and specificity. Its design features a first mutant-VHH against the p19 subunit of human IL-23 and a second VHH engineered to target human TNF, covalently linked via a flexible (G4S)3 peptide linker. The small molecular size and single-domain structure of nanobodies confer enhanced tissue penetration, high stability, and potential for superior pharmacokinetics compared to conventional antibodies. These attributes are particularly advantageous in the context of inflammatory bowel disease, where deep tissue infiltration and resilience in harsh inflammatory microenvironments are critical for therapeutic efficacy.

Target

IL-23 and TNF are key pro-inflammatory cytokines implicated in the pathogenesis of autoimmune conditions, especially inflammatory bowel disease. IL-23 is a dimeric cytokine primarily produced by antigen-presenting cells and plays a pivotal role in regulating the Th17 immune response. TNF is a major pro-inflammatory mediator secreted by macrophages, T cells, and other immune cells, orchestrating inflammation and tissue injury. Both IL-23 and TNF are expressed in inflamed intestinal tissues during disease flares. Targeting IL-23 and TNF is a validated strategy in inflammatory bowel disease therapy, as they contribute to chronic inflammation, epithelial barrier disruption, and ongoing mucosal damage. By simultaneously engaging IL-23 and TNF, VHH-P525 offers strategic value, potentially enhancing clinical outcomes compared to monotherapies. Dual targeting addresses multiple disease mechanisms, providing a comprehensive approach to inflammatory regulation.

Mechanism of Action

VHH-P525 achieves its therapeutic effect by simultaneously binding and neutralizing IL-23 and TNF, two cytokines central to immune activation and chronic inflammation in inflammatory bowel disease. By directly inhibiting IL-23, the nanobody blocks the signaling cascade that promotes Th17 differentiation and pro-inflammatory cytokine release. Concurrently, neutralization of TNF impedes downstream pro-inflammatory events and tissue injury. This dual signal transduction modulation disrupts key pathological loops that perpetuate intestinal inflammation. Beyond traditional nanobody functions, the modular platform allows further extension into formats such as antibody-drug conjugates (ADCs) or bispecifics, illustrating the versatility and adaptability of this therapeutic approach for broader immunological applications.

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) encompasses a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. The prevalence of IBD is increasing globally, placing significant burden on healthcare systems and patient quality of life. Standard therapies include immunosuppressants, corticosteroids, and biologics targeting specific cytokines such as TNF or integrins. However, many patients experience suboptimal responses, adverse effects, or eventually lose therapeutic benefit over time, underlining the need for innovative treatment strategies. Current unmet needs include sustained remission rates, prevention of disease progression, and reduction in systemic side effects. The dual-targeting approach of VHH-P525 offers the potential to address these challenges by more comprehensively modulating the inflammatory milieu, paving the way for improved management and long-term outcomes for patients with IBD.